ORIGINAL RESEARCH article
Front. Cell. Infect. Microbiol.
Sec. Clinical Infectious Diseases
This article is part of the Research TopicPerspectives in Clinical Infectious Diseases: 2024/2025View all 22 articles
Clinical and Molecular Features of Candidemia: A Three-Year Retrospective Study in Northern Guizhou, China
Provisionally accepted- 1Department of Laboratory Medicine, Affiliated Hospital of Zunyi Medical University, Guizhou, China, Zunyi, China
- 2Department of Dermatology, Affiliated Hospital of Zunyi Medical University, Guizhou, China, Zunyi, China
- 3Department of Laboratory Medicine, Renji Hospital, School of Medicine, Chongqing University, Chongqing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: Candidemia, a life-threatening infection with rising incidence and substantial mortality, necessitates improved management strategies. This study aimed to investigate the clinical features, species distribution, risk factors, antifungal susceptibility, and molecular epidemiology of Candida albicans isolates from candidemia patients over a three-year period. Methods: This retrospective study included 133 patients with candidemia from a teaching hospital in Guizhou, China between December 2019 and November 2022. Clinical data were compared between C. albicans (n = 63) and non-C. albicans (NAC) (n = 70) groups. Risk factors and prognostic biomarkers were identified using logistic regression and ROC analysis. Multilocus sequence typing (MLST) was performed for C. albicans isolates. Results: NAC species predominated (52.6%) over C. albicans (47.4%). The 30-day all-cause mortality was 48.1%, higher in C. albicans infections. For C. albicans, hypoalbuminemia and septic shock were independent mortality risk factors, while antifungal therapy and higher platelets were protective. For NAC, septic shock and elevated serum urea were risk factors. Prognostic biomarkers included D-dimer and CRP for C. albicans, and serum urea and total bilirubin for NAC. Most isolates were antifungal-susceptible, though C. glabrata and C. tropicalis showed increased azole non-susceptibility. MLST of 48 C. albicans isolates identified 7 novel alleles and 23 new DST types. CC9 was the predominant clonal complex. CC138 and CC139 are newly reported clonal complexes. Conclusion: This study confirms that candidemia remains a serious threat with high mortality. The distinct risk factors and prognostic biomarkers between C. albicans and non-C. albicans species indicate the need for species-specific management. Although overall resistance remains low, emerging azole non-susceptibility in key species underscores the necessity for continuous susceptibility surveillance. MLST revealed a highly diverse and evolving C. albicans population, This is a provisional file, not the final typeset article including novel genetic lineages. Integrating molecular epidemiology with clinical data is crucial for advancing global candidemia management.
Keywords: Candidemia, Clinical Characteristics, Prognostic risk factors, antifungalsusceptibility, Multilocus Sequence Typing
Received: 08 Sep 2025; Accepted: 24 Nov 2025.
Copyright: © 2025 Chen, Nie, Chen, Liu, Wang, Peng, Luo, Chen, Zhou, Min and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Xun Min, minxunzmu@163.com
Jian Huang, 81537648@qq.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
